995 related articles for article (PubMed ID: 34012451)
1. Differentiation and Regulation of T
Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
Front Immunol; 2021; 12():669474. PubMed ID: 34012451
[TBL] [Abstract][Full Text] [Related]
2. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Reprogramming of CD4
Renaude E; Kroemer M; Borg C; Peixoto P; Hervouet E; Loyon R; Adotévi O
Front Immunol; 2021; 12():669992. PubMed ID: 34262562
[TBL] [Abstract][Full Text] [Related]
4. Emerging Roles of Th9 Cells as an Anti-tumor Helper T Cells.
Chandwaskar R; Awasthi A
Int Rev Immunol; 2019; 38(5):204-211. PubMed ID: 31401904
[TBL] [Abstract][Full Text] [Related]
5. Th9 Cell Differentiation and Its Dual Effects in Tumor Development.
Chen T; Guo J; Cai Z; Li B; Sun L; Shen Y; Wang S; Wang Z; Wang Z; Wang Y; Zhou H; Cai Z; Ye Z
Front Immunol; 2020; 11():1026. PubMed ID: 32508847
[TBL] [Abstract][Full Text] [Related]
6. T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells.
Wang W; Sung N; Gilman-Sachs A; Kwak-Kim J
Front Immunol; 2020; 11():2025. PubMed ID: 32973809
[TBL] [Abstract][Full Text] [Related]
7. Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment.
Guisier F; Barros-Filho MC; Rock LD; Strachan-Whaley M; Marshall EA; Dellaire G; Lam WL
Adv Exp Med Biol; 2020; 1224():35-51. PubMed ID: 32036603
[TBL] [Abstract][Full Text] [Related]
8. Editorial: CD4
González-Navajas JM; Elkord E; Lee J
Front Immunol; 2021; 12():737615. PubMed ID: 34552596
[No Abstract] [Full Text] [Related]
9. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
11. T
Rivera Vargas T; Humblin E; Végran F; Ghiringhelli F; Apetoh L
Semin Immunopathol; 2017 Jan; 39(1):39-46. PubMed ID: 27832300
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.
Tosolini M; Kirilovsky A; Mlecnik B; Fredriksen T; Mauger S; Bindea G; Berger A; Bruneval P; Fridman WH; Pagès F; Galon J
Cancer Res; 2011 Feb; 71(4):1263-71. PubMed ID: 21303976
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.
Janikashvili N; LaCasse CJ; Larmonier C; Trad M; Herrell A; Bustamante S; Bonnotte B; Har-Noy M; Larmonier N; Katsanis E
Blood; 2011 Feb; 117(5):1555-64. PubMed ID: 21123824
[TBL] [Abstract][Full Text] [Related]
14. The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy.
Lee J; Lozano-Ruiz B; Yang FM; Fan DD; Shen L; González-Navajas JM
Front Immunol; 2021; 12():625667. PubMed ID: 33777008
[TBL] [Abstract][Full Text] [Related]
15. Tissue-resident memory CD8
Wang T; Shen Y; Luyten S; Yang Y; Jiang X
Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
[TBL] [Abstract][Full Text] [Related]
16. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
17. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
Brightman SE; Naradikian MS; Miller AM; Schoenberger SP
J Leukoc Biol; 2020 Apr; 107(4):625-633. PubMed ID: 32170883
[TBL] [Abstract][Full Text] [Related]
18. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.
Xiang J; Huang H; Liu Y
J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL-specific CD4
Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
[TBL] [Abstract][Full Text] [Related]
20. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
